Kawasaki - AHA Statment Summary

Introduction And Epidemiology

• Constitutes acute self-limited febrile illness.
• Primarily affects children under five years of age.
• Represents leading cause of acquired pediatric heart disease in developed nations.
• Carries twenty-five percent risk of coronary artery dilation or aneurysms if left untreated.
• Demonstrates highest incidence in northeast Asian countries including Japan, South Korea, China, Taiwan.
• Pathogenesis remains completely unknown.

Diagnosis And Clinical Features

• Remains purely clinical diagnosis lacking pathognomonic diagnostic test.
• Standard diagnosis requires four days of fever.
• Experienced clinicians may establish diagnosis after three days of fever.
• Early diagnosis within ten days of fever onset remains crucial to prevent coronary dilation.

Complete Diagnostic Criteria

• Requires four out of five principal clinical features.
• Polymorphous rash.
• Bilateral nonexudative conjunctival injection.
• Extremity changes including erythema, swelling, or subsequent peeling.
• Oropharyngeal changes including strawberry tongue, erythematous lips.
• Cervical lymphadenopathy, usually unilateral, measuring greater than 1.5 centimeters.

Incomplete Kawasaki Disease

• Features prolonged unexplained fever.
• Manifests fewer than four principal clinical features.
• Diagnosed via compatible laboratory or echocardiographic findings.

Kawasaki Disease Shock Syndrome

• Constitutes rare, severe illness form.
• Presents with vasodilatory shock, severe hypotension, poor systemic perfusion.
• Frequently presents with elevated C-reactive protein, hypoalbuminemia, severe thrombocytopenia.
• Carries significantly increased risk for intravenous immunoglobulin resistance and coronary abnormalities.
• Demands immediate intensification of initial therapy.

Differentiating Multisystem Inflammatory Syndrome In Children

• Presents as differential diagnosis since emergence of SARS-CoV-2.
• Features prominent gastrointestinal symptoms including abdominal pain, vomiting, diarrhea.
• Frequently involves prominent headache.
• Laboratory profile reveals marked thrombocytopenia, lymphopenia, elevated troponin, elevated brain natriuretic peptide.
• Cardiac evaluation demonstrates decreased left ventricular systolic function, pericardial effusion.
• Machine learning algorithms assist in clinical differentiation.

High-Risk Criteria For Coronary Artery Aneurysms

• Identifies candidates for intensified primary anti-inflammatory therapy.
• Age under six months constitutes universally accepted high-risk feature.
• Baseline echocardiogram demonstrating coronary artery Z score greater than or equal to 2.5 establishes high risk.
• North American risk score assigns points for age under six months, Asian race, Z score over 2, C-reactive protein over 13 mg/dL.
• Risk score of 3 or greater strongly predicts aneurysm development by 8 weeks.

Cardiac Imaging In Acute Phase

Echocardiography Standards

• Serves as primary, noninvasive imaging modality.
• Mandates highest-frequency transducer possible.
• Requires accurate patient weight and height for precise body surface area calculation.
• Centers must utilize consistent Z score equations sequentially to prevent risk classification errors.
• Baseline normal echocardiogram does not exclude future aneurysm development.
• Repeat imaging indicated before hospital discharge for high-risk patients.
• Myocardial dysfunction with reduced shortening fraction occurs in twenty percent of patients at diagnosis.

Imaging Target	Recommended Views	Clinical Assessment Protocol
Left Main Coronary Artery	Parasternal short axis, parasternal long axis, subcostal ventricular long axis.	Evaluate for presence of aneurysms or thrombus.
Left Anterior Descending	Parasternal short axis, parasternal long axis.	Quantify left ventricular ejection fraction and strain.
Right Coronary Artery	Parasternal short axis, parasternal long axis, subcostal views.	Assess regional wall motion abnormalities.
Posterior Descending	Apical 4-chamber, subcostal atrial long axis.	Evaluate presence of atrioventricular regurgitation.
Additional Structures	Parasternal long axis, apical views.	Assess pericardial effusion size, aortic root dimensions.

Quantitative Z-Score Classification

Classification Category	Z Score Range Criteria	Clinical Significance
No Involvement	Less than 2.	Normal baseline dimensions.
Dilation Only	2 to less than 2.5.	Warrants follow-up 1 to 2 weeks post-discharge.
Small Aneurysm	2.5 to less than 5.	Repeat imaging twice weekly until progression stops.
Medium Aneurysm	5 to less than 10.	Absolute dimension strictly less than 8 millimeters.
Large Or Giant Aneurysm	10 or greater.	Absolute dimension 8 millimeters or greater.

Acute Medical Management

Standard Initial Therapy

Medication	Dosage And Administration	Clinical Considerations
Intravenous Immunoglobulin	2 g/kg infused over 8 to 12 hours.	Consider lean body mass dosing in obesity to prevent hemolytic anemia. Defer live vaccines for 11 months.
Aspirin (High/Moderate Dose)	30 to 50 mg/kg/day divided every 6 hours initially.	Recent studies show no outcome difference compared to low-dose therapy. Efficacy reduced by nonsteroidal anti-inflammatory drugs.
Aspirin (Low Dose)	3 to 5 mg/kg/day once daily.	Initiated after patient remains afebrile for 48 to 72 hours.

Intensification Therapy For High-Risk Patients

• Strongly indicated for baseline Z score 2.5 or greater.
• Strongly indicated for infants under six months of age.
• Goal involves reducing progressive coronary artery expansion.

Intensification Agent	Dosage And Administration	Clinical Considerations
Corticosteroids	Methylprednisolone 2 mg/kg/day intravenously divided every 12 hours for 5 days.	Requires famotidine ulcer prophylaxis. Tapered slowly over 2 to 4 weeks once C-reactive protein normalizes.
Infliximab	10 mg/kg intravenously given over 2 hours.	Monoclonal antibody targeting tumor necrosis factor alpha.
Etanercept	0.8 mg/kg subcutaneously weekly for 3 doses.	Soluble receptor binding tumor necrosis factor alpha.

Management Of Intravenous Immunoglobulin Resistance

• Defined strictly as persistent or recrudescent fever 36 hours post initial infusion completion.
• Carries profoundly increased risk for developing coronary artery aneurysms.

Rescue Agent	Trial Data And Efficacy	Additional Directives
Prednisolone	RAISE trial demonstrated lower incidence of coronary abnormalities.	2 mg/kg/day intravenously for 5 days. Validated primarily in Japanese populations.
Infliximab	KIDCARE trial demonstrated shorter fever duration, reduced hospitalization.	Serves as highly effective second-line alternative.
Cyclosporine	KAICA trial demonstrated lower incidence of early coronary abnormalities.	5 mg/kg/day orally divided every 12 hours. Requires daily magnesium supplementation to prevent hypomagnesemia.
Anakinra	Phase II trials demonstrated safety and rapid fever cessation.	10 mg/kg/day intravenously preferred over subcutaneous route during hospitalization.

Additional Therapies For Refractory Disease

Medication	Primary Indication	Clinical Considerations
Cyclophosphamide	Refractory giant aneurysms actively progressing despite multiple therapies.	10 mg/kg/day intravenously. Mandates aggressive hydration and rheumatology consultation.
Statins (Atorvastatin)	Acute severe aneurysms under investigation.	Improves endothelial cell homeostasis, blocks endothelial to mesenchymal transition.

Antithrombotic And Anticoagulation Therapy

• Large aneurysms harbor severe risk for luminal thrombosis.
• Requires dual approach combining antiplatelet agents and systemic anticoagulation.
• Dual antiplatelet therapy considered for any aneurysm reaching Z score 5 or greater.
• Clopidogrel (1 mg/kg/day) serves as primary alternative for aspirin allergy.
• Warfarin therapy historically standard but requires intensive monitoring.
• Low molecular weight heparin historically standard but mandates painful twice-daily pediatric injections.
• Direct oral anticoagulants provide highly attractive, targeted alternative.
• Apixaban demonstrated profound safety lacking thromboembolic events in pediatric cardiac disease trial.
• Edoxaban demonstrated equivalent efficacy to standard anticoagulants.
• Reversal agents including prothrombin concentrates and andexanet alfa available for massive bleeding complications.

Management Of Acute Myocardial Infarction

• Risk peaks dramatically during first 2 to 3 months following illness onset.
• Lifetime ongoing ischemia risk persists indefinitely for patients harboring large or giant aneurysms.
• Presents atypically compared to adult atherosclerotic disease.
• Infants manifest nonspecific pain, unexplained crying, severe restlessness, unusual pallor, profuse sweating.
• Older children exhibit chest pain, breathlessness, unexplained vomiting, focal skin discoloration.
• Requires immediate coordinated response from multidisciplinary cardiovascular heart team.
• ST-segment elevation myocardial infarction mandates percutaneous coronary intervention within 90 minutes.
• Medical thrombolysis utilizing tissue-type plasminogen activator indicated if patient size precludes catheterization.
• Post-infarction medical therapy integrates aspirin, beta-blockers, statins, angiotensin-converting enzyme inhibitors.

Long-Term Management And Risk Stratification

• Long-term trajectory strictly determined by maximal coronary artery Z score achieved during acute phase.
• Small aneurysms exhibit near-universal normalization of internal lumen diameter over time.
• Complete regression of small aneurysms carries near-zero long-term risk of adverse cardiac events.
• Stable regressed aneurysms warrant decreased frequency of surveillance visits.

Risk Level Classification And Follow-Up Protocol

Maximal Risk Level	Associated Coronary Status	Required Surveillance Protocol	Chronic Medical Therapy
Level 1	Normal architecture.	Assessment at 4 to 6 weeks.	Low-dose aspirin for 6 weeks.
Level 2	Dilation strictly resolving.	Assessment at 1 to 2 weeks, then 1 year.	Low-dose aspirin for 6 weeks.
Level 3.1	Persistent small aneurysm.	Echocardiogram at 6 weeks, 6 months, 12 months, then yearly.	Continuous low-dose aspirin.
Level 4.1	Persistent medium aneurysm.	Echocardiogram at 6 weeks, 3 months, 6 months, 12 months, then yearly.	Low-dose aspirin plus clopidogrel.
Level 5.1	Persistent large/giant aneurysm.	Echocardiogram every 6 to 12 months long-term.	Low-dose aspirin, dual antiplatelets, plus systemic anticoagulation.

Advanced Surveillance Imaging

• Transthoracic echocardiogram serves as standard primary surveillance tool.
• Demonstrates lower sensitivity for detecting distal coronary aneurysms compared to advanced modalities.

Computed Tomography Angiography

• Visualizes entire coronary tree comprehensively.
• Reliably assesses aneurysm morphology, strictures, thrombosis, and stenosis exceeding fifty percent.
• Possesses superior spatial resolution compared to magnetic resonance imaging for evaluating distal lesions.
• Radiation exposure successfully mitigated by modern dual-source technology limiting dose below 1 mSv.
• Detects profound late-stage vessel calcifications occurring decades following acute illness.
• Serves as recommended 1-year baseline evaluation for patients with large or giant aneurysms.
• Computed tomography-derived fractional flow reserve models hemodynamic flow to evaluate severity of stenotic lesions.

Cardiovascular Magnetic Resonance Imaging

• Evaluates complete ventricular function and tissue characteristics entirely without radiation.
• Ferumoxytol-enhanced angiography facilitates excellent visualization of coronary walls.
• Identifies critical myocardial fibrosis utilizing T1 mapping and late gadolinium enhancement.
• Detects myocardial inflammation utilizing T2 mapping.
• Safely identifies inducible perfusion defects utilizing regadenoson or adenosine pharmacologic stress testing.

Invasive Coronary Angiography

• Delineates complex coronary architecture, discrete stenoses, collateral vessel formation.
• Strictly reserved for percutaneous revascularization planning.
• Utilizes fractional flow reserve assessing pressure differences directly across stenotic lesions.
• Incorporates intravascular ultrasound offering superior spatial resolution of wall morphology and plaque composition.
• Incorporates optical coherence tomography visualizing micro-structural changes within coronary wall.

Assessment Of Inducible Ischemia

• Mandated for patients harboring Z scores of 10 or greater due to exceptional risk.
• High cumulative incidence of severe luminal narrowing necessitates scheduled surveillance regardless of symptomatic status.
• Exercise stress echocardiography serves as preferred, radiation-free screening tool for children over 7 years.
• Dobutamine pharmacologic stress echocardiography successfully identifies wall motion abnormalities in infants unable to exercise.

Health Care Transition

• Structured, protocol-driven health care transition remains absolutely paramount.
• Medical teams must aggressively plan seamless transfer into adult cardiology networks.
• Employs Six Core Elements framework encompassing structured planning, structured transfer, adult care integration.
• Adult cardiologists must manage long-term consequences including acute coronary syndrome, progressive heart failure, arrhythmias.
• Pregnant women with established giant aneurysms receiving systemic anticoagulation require immediate high-risk obstetrics referral coupled with intensive cardiology consultation.